← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Albemarle's lithium downturn drove lower revenue, a large loss and negative operating margin, but positive free cash flow provided liquidity through commodity stress.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 4.4%Watch
- Profitability — The net loss narrowed from $1.179B to $510.628MOK
- Cash flow — Free cash flow turned positive at $692.466M from an outflow of $992.653MOK
- Margins — Operating margin expanded 2590 bps to -7.14%OK
- Accounting — Lithium-cycle loss with positive cash flowWatch
- Insiders — 0 purchases and 6 salesNote
Business
Albemarle produces lithium, bromine and specialty chemicals.
Where the revenue comes from
Fiscal 2025, as ALBEMARLE CORP reports it. History and quarterly detail are in the app.
- Energy Storage$2.7B
- Specialties$1.4B
- Ketjen$1.1B
Leadership changes
From ALBEMARLE CORP's own filings, the day they're filed.
- Donald J. LaBauve Jr · Chief Accounting Officer · departureeff. 2026-06-02
- Neal R. Sheorey · Chief Financial Officer · departureeff. 2026-06-02
- Donald J. LaBauve Jr · Chief Accounting Officer · departureeff. 2026-06-01
Latest filings
- 8-K · Company announcement2026-09-03
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-23
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ALBEMARLE CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.